Khattar Jack A.

Khattar Jack A., President and CEO, has demonstrated a clear selling bias in recent insider transactions, primarily involving shares of Supernus Pharmaceuticals (SUPN). Since September 2025, Khattar has executed eight sales totaling approximately $7.9 million, with the most significant transactions occurring in March 2026. On March 13, 2026, he sold shares worth $547,842 and $1.21 million, following a $907,095 sale on March 6. Earlier disposals include a $2.95 million transaction on October 9, 2025, and a $1.93 million sale on October 1, 2025. These sales contrast with his historical activity, which includes $10.75 million in total buys against $21.93 million in sells across 51 reported transactions—all concentrated in SUPN, with no recent purchases. The transactions suggest a consistent reduction in Khattar’s SUPN holdings, with sales often executed in clusters. Notably, the March 2026 disposals were preceded by a lull in activity after October 2025. While some filings show derivative transactions (codes F, M) with zero or minimal reported value, the bulk of the monetization comes from open-market sales (code S). Khattar’s trading history is exclusively tied to SUPN, with no disclosed activity in other equities beyond a series of zero-value dispositions (code D) and an unspecified transaction (code U) involving scPharmaceuticals (SCPH) in October 2025. The pattern reflects a prolonged unwind of positions rather than short-term profit-taking.